News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Lundberg Sven Ante
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/02/2023 |
4
| Lundberg Sven Ante (Director) has filed a Form 4 on Vor Biopharma Inc.|
Txns:
| Granted 30,000 options to buy
@ $4.79, valued at
$143.7k
|
|
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/03/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/24/2022 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 08/23/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/22/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/13/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/16/2022 |
4
| Lundberg Sven Ante (Director) has filed a Form 4 on Vor Biopharma Inc.|
Txns:
| Granted 16,911 options to buy
@ $4.26, valued at
$72k
|
|
| 02/02/2022 |
4
| Lundberg Sven Ante (President, CEO & PFO) has filed a Form 4 on Merus N.V.|
Txns:
| Granted 295,000 options to buy
@ $24.61, valued at
$7.3M
|
|
| 08/04/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/12/2021 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 03/29/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/03/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/18/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/09/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/04/2021 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 01/06/2020 |
4
| Lundberg Sven Ante (President, CEO & PFO) has filed a Form 4 on Merus N.V.|
Txns:
| Granted 414,917 options to buy
@ $13.52, valued at
$5.6M
|
|
| 01/02/2020 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 02/10/2017 |
4
| Lundberg Sven Ante (Chief Scientific Officer) has filed a Form 4 on CRISPR Therapeutics AG|
Txns:
| Converted 55,217 shares
@ $0
Bought 400 shares
@ $14, valued at
$5.6k
Converted 55,217 options to buy
@ $0 |
|
| 10/18/2016 |
3
| Form 3 - Initial statement of beneficial ownership of securities |
|
|